Competitive Binding Technology
Active-site/Ligand Binding Technology Overview
DiscoverX's proprietary active-site/ligand binding technology affords investigators the ability to leverage a growing portfolio of services against multiple target classes and maximixe the value of novel and chemistry assets through all stages of drug discovery. This robust and reliable assay technology enables accurate, precise, reproducible and quantitative measurements of interactions between test compounds and the target protein.
Explore Target Biology With Multiple Technology Platforms
KINOMEscan℠ Active-site Directed Competition Binding Platform
screening platform employs a novel and proprietary active site-directed competition binding assay to quantitatively measure interactions between test compounds and more than 450 kinase assays and disease relevant mutant variants.
Learn more about the KINOMEscan Assay Platform >
BROMOscan℠ Bromodomain-ligand Binding Platform
Based on the proven KINOMEscan℠
technology platform, BROMOscan℠
employs a novel and proprietary bromodomain-ligand binding assay to quantitatively measure interactions between test compounds and a panel of bromodomain assays.
Learn more about BROMOscan Assay Platform
InCELL Hunter™ Intracellular Binding Assay Platform
Employing EFC, the catalytic domain of the protein of interest is tagged with enhanced ProLabel (ePL). Complementation between the ePL and EA occurs only when compounds bind to the catalytic domain and stabilizes the protein of interest, increasing its half-life relative to the unbound protein.
Learn more about InCELL Assay Platform >